Document is current
Any future updates will be listed below
-
Authors
Hardcastle, Nicholas http://orcid.org/0000-0001-7796-8472
Cook, Olivia
Ray, Xenia
Moore, Alisha
Moore, Kevin L.
Pryor, David
Rossi, Alana
Foroudi, Farshad
Kron, Tomas
Siva, Shankar http://orcid.org/0000-0003-2840-0658
-
Funding
Funding for this research was provided by:
Varian Medical Systems
- License Information
-
More Information
Article History
Received: 8 March 2021
Accepted: 12 May 2021
First Online: 3 August 2021
Declarations
:
: All participants consented to participate in the FASTRACK II clinical trial. Ethics approval was provided by Peter MacCallum Cancer Centre.
: Not applicable.
: KLM reports grants, personal fees and non-financial support from Varian Medical Systems, outside the submitted work. In addition, KLM has a patent Developing Predictive Dose-Volume Relationships for a Radiotherapy Treatment licensed to Varian Medical Systems, and a patent Knowledge-based prediction of three-dimensional dose distributions licensed to Varian Medical Systems. SS has received speaker fee for educational event or scientific meeting from Varian Medical Systems.
